Post Kala-azar Dermal Leishmaniasis (PKDL)

Post Kala-azar Dermal Leishmaniasis, or PKDL, is a skin condition that can develop after someone has been treated for visceral leishmaniasis. Visceral leishmaniasis is a serious infection caused by a parasite called Leishmania. It affects internal organs like the spleen and liver.

PKDL appears as skin changes, usually weeks to years after the initial infection has been treated. The condition shows up as a rash, patches, or nodules on the skin. Most cases occur in people who live in or have traveled to areas where leishmaniasis is common, including parts of East Africa and South Asia.

The skin symptoms happen because parasites remain in the body even after treatment for the internal infection. These parasites settle in skin tissue and cause visible changes. PKDL is not contagious through casual contact, but sandfly bites from an infected person can spread the parasite to others.

PKDL causes visible changes to the skin that can vary from person to person. Common symptoms include:

• Light colored or hypopigmented patches on the face, arms, or trunk
• Flat reddish spots or papules that may spread over time
• Raised bumps or nodules on the skin
• Skin lesions that do not itch or cause pain in most cases
• Facial skin changes that may affect appearance
• Gradual spread of skin patches over months or years

Some people with PKDL have mild symptoms that go unnoticed at first. Others develop more visible skin changes that affect their quality of life and social interactions.

PKDL develops when Leishmania parasites persist in the body after treatment for visceral leishmaniasis. The parasites move from internal organs to the skin, where they cause visible changes. Scientists believe the immune system plays a role in how PKDL develops, though the exact mechanism is not fully understood.

Risk factors include living in or traveling to areas where leishmaniasis is common, previous infection with visceral leishmaniasis, and incomplete or inadequate treatment of the original infection. The condition occurs more frequently in certain regions, with different patterns in East Africa compared to South Asia. A weakened immune system may increase the likelihood of developing PKDL after treatment for visceral leishmaniasis.

Doctors diagnose PKDL by examining the skin and reviewing medical history, especially past visceral leishmaniasis infection. A skin biopsy may be taken to look for Leishmania parasites under a microscope. Laboratory tests can detect antibodies against the parasite in blood samples.

Blood tests like Leishmania Ab IgG can help identify exposure to the parasite and may show elevated levels that persist after treatment. Specialized testing beyond routine blood panels is often needed for accurate diagnosis. Talk to a doctor about testing if you have a history of leishmaniasis and develop new skin symptoms.

Treatment for PKDL focuses on eliminating the remaining parasites and helping the skin heal. Options include:

• Antiparasitic medications like miltefosine or liposomal amphotericin B
• Extended treatment courses that may last several weeks or months
• Close monitoring by a doctor with experience treating leishmaniasis
• Nutritional support to help the immune system function properly
• Skin care to manage visible lesions and prevent secondary infections
• Follow-up testing to ensure parasites are cleared from the body

Treatment success depends on early diagnosis and completing the full medication course. Some cases resolve on their own, but medical treatment reduces the risk of spreading the parasite and speeds healing.